Vitamin D in autoimmune liver disease

Clinics and Research in Hepatology and Gastroenterology

Volumn 37, Issue 5, 2013, Pages 535-545

  Smyk, Daniel S ^a   Orfanidou, Timoklia ^b   Invernizzi, Pietro ^c   Bogdanos, Dimitrios P ^a,b,d   Lenzi, Marco ^e  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b Cellular Immunotherapy and Molecular Immunodiagnostics   (Greece)

^c HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^d UNIVERSITY OF THESSALY   (Greece)

^e UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

25(OH)D; AIH; AMA; ANA; BECs; CIS; CSF; DBP; EBNA1; EBV; GWAS; MS; PBC; PDC; PSC; UDCA; VDR

Indexed keywords

CATHELICIDIN; GLYCOSYLATED PROTEIN; LIPOPROTEIN; MITOCHONDRION ANTIBODY; URSODEOXYCHOLIC ACID; VITAMIN D; VITAMIN D BINDING PROTEIN; VITAMIN D RECEPTOR;

ANGIOGENESIS; APOPTOSIS; AUTOIMMUNE HEPATITIS; AUTOIMMUNE LIVER DISEASE; AUTOIMMUNITY; B LYMPHOCYTE; CELL PROLIFERATION; COMPARATIVE STUDY; DEMYELINATION; DENDRITIC CELL; DIABETES MELLITUS; DIFFERENTIATION; ENTERITIS; ENVIRONMENTAL FACTOR; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC TRAIT; GLIOSIS; GRAVES DISEASE; HASHIMOTO DISEASE; HEPATITIS C; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; IMMUNOREACTIVITY; INSULIN DEPENDENT DIABETES MELLITUS; MACROPHAGE; MONOCYTE; MULTIPLE SCLEROSIS; OSTEOPOROSIS; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; REVIEW; RHEUMATOID ARTHRITIS; SINGLE NUCLEOTIDE POLYMORPHISM; T LYMPHOCYTE; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; VITAMIN D METABOLISM; VITAMIN SUPPLEMENTATION;

25(OH)D; 25-HYDROXYVITAMIN D; AIH; AMA; ANA; ANTI-MITOCHONDRIAL ANTIBODY; ANTI-NUCLEAR ANTIBODY; AUTOIMMUNE HEPATITIS; BECS; BILIARY EPITHELIAL CELLS; CEREBROSPINAL FLUID; CIS; CLINICALLY ISOLATED SYNDROME; CSF; DBP; EBNA1; EBV; EPSTEIN-BARR NUCLEAR ANTIGEN 1; EPSTEIN-BARR VIRUS; GENOME WIDE ASSOCIATION STUDY; GWAS; MS; MULTIPLE SCLEROSIS; PBC; PDC; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; PSC; PYRUVATE DEHYDROGENASE COMPLEX; UDCA; URSODEOXYCHOLIC ACID; VDR; VITAMIN D BINDING PROTEIN; VITAMIN D RECEPTOR;

AUTOIMMUNE DISEASES; CELL PROLIFERATION; CYTOKINES; GENOTYPE; HUMANS; IMMUNOMODULATION; LIVER DISEASES; MULTIPLE SCLEROSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, CALCITRIOL; T-LYMPHOCYTES; VITAMIN D; VITAMIN D DEFICIENCY; VITAMIN D-BINDING PROTEIN;

EID: 84886946222     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/j.clinre.2013.05.016     Document Type: Short Survey

References (149)

1. Agmon-Levin N., Blank M., Zandman-Goddard G., Orbach H., Meroni P.L., Tincani A., et al. Vitamin D: an instrumental factor in the anti-phospholipid syndrome by inhibition of tissue factor expression. Ann Rheum Dis 2011, 70:145-150.
2. Agmon-Levin N., Kivity S., Tzioufas A.G., Lopez Hoyos M., Rozman B., Efes I., et al. Low levels of vitamin-D are associated with neuropathy and lymphoma among patients with Sjogren's syndrome. J Autoimmun 2012, 39:234-239.
3. Agmon-Levin N., Theodor E., Segal R.M., Shoenfeld Y. Vitamin D in systemic and organ-specific autoimmune diseases. Clin Rev Allergy Immunol 2012, [Epub ahead of print].
4. Amital H., Szekanecz Z., Szucs G., Danko K., Nagy E., Csepany T., et al. Serum concentrations of 25-OH vitamin D in patients with systemic lupus erythematosus (SLE) are inversely related to disease activity: is it time to routinely supplement patients with SLE with vitamin D?. Ann Rheum Dis 2010, 69:1155-1157.
5. Arnson Y., Amital H., Agmon-Levin N., Alon D., Sanchez-Castanon M., Lopez-Hoyos M., et al. Serum 25-OH vitamin D concentrations are linked with various clinical aspects in patients with systemic sclerosis: a retrospective cohort study and review of the literature. Autoimmun Rev 2011, 10:490-494.
6. Hajas A., Sandor J., Csathy L., Csipo I., Barath S., Paragh G., et al. Vitamin D insufficiency in a large MCTD population. Autoimmun Rev 2011, 10:317-324.
7. Lerner A., Shapira Y., Agmon-Levin N., Pacht A., Ben-Ami Shor D., Lopez H.M., et al. The clinical significance of 25OH-Vitamin D status in celiac disease. Clin Rev Allergy Immunol 2012, 42:322-330.
8. Oren Y., Shapira Y., Agmon-Levin N., Kivity S., Zafrir Y., Altman A., et al. Vitamin D insufficiency in a sunny environment: a demographic and seasonal analysis. Isr Med Assoc J 2010, 12:751-756.
9. Toubi E., Shoenfeld Y. The role of vitamin D in regulating immune responses. Isr Med Assoc J 2010, 12:174-175.
10. Kivity S., Agmon-Levin N., Zisappl M., Shapira Y., Nagy E.V., Danko K., et al. Vitamin D and autoimmune thyroid diseases. Cell Mol Immunol 2011, 8:243-247.
11. Holick M.F. Vitamin D deficiency. N Engl J Med 2007, 357:266-281.
12. Speeckaert M., Huang G., Delanghe J.R., Taes Y.E. Biological and clinical aspects of the vitamin D binding protein (Gc-globulin) and its polymorphism. Clin Chim Acta 2006, 372:33-42.
13. Eloranta J.J., Wenger C., Mwinyi J., Hiller C., Gubler C., Vavricka S.R., et al. Association of a common vitamin D-binding protein polymorphism with inflammatory bowel disease. Pharmacogenet Genomics 2011, 21:559-564.
14. Papiha S.S., Pal B. Gc (vitamin D binding protein) subtypes in rheumatoid arthritis. Hum Genet 1985, 70:278-280.
15. Arnaud J., Constans J. Affinity differences for vitamin D metabolites associated with the genetic isoforms of the human serum carrier protein (DBP). Hum Genet 1993, 92:183-188.
16. Kamboh M.I., Ferrell R.E. Ethnic variation in vitamin D-binding protein (GC): a review of isoelectric focusing studies in human populations. Hum Genet 1986, 72:281-293.
17. Falleti E., Bitetto D., Fabris C., Fattovich G., Cussigh A., Cmet S., et al. Vitamin D binding protein gene polymorphisms and baseline vitamin D levels as predictors of antiviral response in chronic hepatitis C. Hepatology 2012, 56(5):1641-1650.
18. Holick M.F. Resurrection of vitamin D deficiency and rickets. J Clin Invest 2006, 116:2062-2072.
19. Kitson M.T., Roberts S.K. D-livering the message: the importance of vitamin D status in chronic liver disease. J Hepatol 2012, 57:897-909.
20. Adorini L. Vitamin D receptor polymorphisms in primary biliary cirrhosis: a functional connection?. J Hepatol 2009, 50:1071-1073.
21. Brown S.J. The role of vitamin D in multiple sclerosis. Ann Pharmacother 2006, 40:1158-1161.
22. Cantorna M.T. Vitamin D and its role in immunology: multiple sclerosis, and inflammatory bowel disease. Prog Biophys Mol Biol 2006, 92:60-64.
23. Handunnetthi L., Ramagopalan S.V. UV radiation, vitamin D, and multiple sclerosis. Proc Natl Acad Sci U S A 2010, 107:E130. [author reply E131].
24. Ahn J., Yu K., Stolzenberg-Solomon R., Simon K.C., McCullough M.L., Gallicchio L., et al. Genome-wide association study of circulating vitamin D levels. Hum Mol Genet 2010, 19:2739-2745.
25. Wang T.J., Zhang F., Richards J.B., Kestenbaum B., van Meurs J.B., Berry D., et al. Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet 2010, 376:180-188.
26. Matilainen J.M., Rasanen A., Gynther P., Vaisanen S. The genes encoding cytokines IL-2, IL-10 and IL-12B are primary 1alpha, 25(OH)2D3 target genes. J Steroid Biochem Mol Biol 2010, 121:142-145.
27. Hunter D., De Lange M., Snieder H., MacGregor A.J., Swaminathan R., Thakker R.V., et al. Genetic contribution to bone metabolism, calcium excretion, and vitamin D and parathyroid hormone regulation. J Bone Miner Res 2001, 16:371-378.
28. Fu L., Yun F., Oczak M., Wong B.Y., Vieth R., Cole D.E. Common genetic variants of the vitamin D binding protein (DBP) predict differences in response of serum 25-hydroxyvitamin D [25(OH)D] to vitamin D supplementation. Clin Biochem 2009, 42:1174-1177.
29. Chun R.F., Peercy B.E., Adams J.S., Hewison M. Vitamin D binding protein and monocyte response to 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D: analysis by mathematical modeling. PloS One 2012, 7:e30773.
30. Bailey R., Cooper J.D., Zeitels L., Smyth D.J., Yang J.H., Walker N.M., et al. Association of the vitamin D metabolism gene CYP27B1 with type 1 diabetes. Diabetes 2007, 56:2616-2621.
31. Lopez E.R., Regulla K., Pani M.A., Krause M., Usadel K.H., Badenhoop K. CYP27B1 polymorphisms variants are associated with type 1 diabetes mellitus in Germans. J Steroid Biochem Mol Biol 2004, 89-90:155-157.
32. Lopez E.R., Zwermann O., Segni M., Meyer G., Reincke M., Seissler J., et al. A promoter polymorphism of the CYP27B1 gene is associated with Addison's disease, Hashimoto's thyroiditis, Graves' disease and type 1 diabetes mellitus in Germans. Eur J Endocrinol 2004, 151:193-197.
33. Orton S.M., Morris A.P., Herrera B.M., Ramagopalan S.V., Lincoln M.R., Chao M.J., et al. Evidence for genetic regulation of vitamin D status in twins with multiple sclerosis. Am J Clin Nutr 2008, 88:441-447.
34. Wang M., Zhang W., Yuan L., Fu G., Wei Q., Zhang Z. Common genetic variants on 8q24 contribute to susceptibility to bladder cancer in a Chinese population. Carcinogenesis 2009, 30:991-996.
35. Arnson Y., Amital H., Shoenfeld Y. Vitamin D and autoimmunity: new aetiological and therapeutic considerations. Ann Rheum Dis 2007, 66:1137-1142.
36. Deluca H.F., Cantorna M.T. Vitamin D: its role and uses in immunology. FASEB J 2001, 15:2579-2585.
37. Chen S., Sims G.P., Chen X.X., Gu Y.Y., Lipsky P.E. Modulatory effects of 1,25-dihydroxyvitamin D3 on human B cell differentiation. J Immunol 2007, 179:1634-1647.
38. Lemire J.M. Immunomodulatory role of 1,25-dihydroxyvitamin D3. J Cell Biochem 1992, 49:26-31.
39. Godfrey D.I., Hammond K.J., Poulton L.D., Smyth M.J., Baxter A.G. NKT cells: facts, functions and fallacies. Immunol Today 2000, 21:573-583.
40. Taniguchi M., Harada M., Kojo S., Nakayama T., Wakao H. The regulatory role of Valpha14 NKT cells in innate and acquired immune response. Annu Rev Immunol 2003, 21:483-513.
41. Cantorna M.T. Why do T cells express the vitamin D receptor?. Ann N Y Acad Sci 2011, 1217:77-82.
42. Yu S., Cantorna M.T. The vitamin D receptor is required for iNKT cell development. Proc Natl Acad Sci U S A 2008, 105:5207-5212.
43. Gascon-Barre M., Demers C., Mirshahi A., Neron S., Zalzal S., Nanci A. The normal liver harbors the vitamin D nuclear receptor in nonparenchymal and biliary epithelial cells. Hepatology 2003, 37:1034-1042.
44. Adorini L. Intervention in autoimmunity: the potential of vitamin D receptor agonists. Cell Immunol 2005, 233:115-124.
45. Munger K.L., Levin L.I., Hollis B.W., Howard N.S., Ascherio A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2006, 296:2832-2838.
46. Willheim M., Thien R., Schrattbauer K., Bajna E., Holub M., Gruber R., et al. Regulatory effects of 1alpha, 25-dihydroxyvitamin D3 on the cytokine production of human peripheral blood lymphocytes. J Clin Endocrinol Metab 1999, 84:3739-3744.
47. Raiotach-Regue D., Grau-Lopez L., Naranjo-Gomez M., Ramo-Tello C., Pujol-Borrell R., Martinez-Caceres E., et al. Stable antigen-specific T-cell hyporesponsiveness induced by tolerogenic dendritic cells from multiple sclerosis patients. Eur J Immunol 2012, 42:771-782.
48. Lemire J.M., Archer D.C., Beck L., Spiegelberg H.L. Immunosuppressive actions of 1,25-dihydroxyvitamin D3: preferential inhibition of Th1 functions. J Nutrition 1995, 125:1704S-1708S.
49. Smolders J., Thewissen M., Peelen E., Menheere P., Tervaert J.W., Damoiseaux J., et al. Vitamin D status is positively correlated with regulatory T cell function in patients with multiple sclerosis. PloS One 2009, 4:e6635.
50. Boonstra A., Barrat F.J., Crain C., Heath V.L., Savelkoul H.F., O'Garra A. 1alpha, 25-Dihydroxyvitamin d3 has a direct effect on naive CD4(+) T cells to enhance the development of Th2 cells. J Immunol 2001, 167:4974-4980.
51. Shoenfeld N., Amital H., Shoenfeld Y. The effect of melanism and vitamin D synthesis on the incidence of autoimmune disease. Nat Clin Pract Rheumatol 2009, 5:99-105.
52. Barzilai O., Sherer Y., Ram M., Izhaky D., Anaya J.M., Shoenfeld Y. Epstein-Barr virus and cytomegalovirus in autoimmune diseases: are they truly notorious? A preliminary report. Ann N Y Acad Sci 2007, 1108:567-577.
53. Kamen D.L., Cooper G.S., Bouali H., Shaftman S.R., Hollis B.W., Gilkeson G.S. Vitamin D deficiency in systemic lupus erythematosus. Autoimmun Rev 2006, 5:114-117.
54. Welsh P., Peters M.J., Sattar N. Is vitamin D in rheumatoid arthritis a magic bullet or a mirage? The need to improve the evidence base prior to calls for supplementation. Arthritis Rheum 2011, 63:1763-1769.
55. Seriolo B., Molfetta L., Cutolo M. Seasonal variations in serum levels of 25-hydroxyvitamin D in patients with systemic sclerosis. Clin Rheumatol 2011, 30:445-446.
56. Hanwell H.E., Banwell B. Assessment of evidence for a protective role of vitamin D in multiple sclerosis. Biochim Biophys Acta 2011, 1812:202-212.
57. Boucher B.J. Vitamin D insufficiency and diabetes risks. Curr Drug Targets 2011, 12:61-87.
58. McCarthy D., Duggan P., O'Brien M., Kiely M., McCarthy J., Shanahan F., et al. Seasonality of vitamin D status and bone turnover in patients with Crohn's disease. Aliment Pharmacol Ther 2005, 21:1073-1083.
59. Antico A., Tampoia M., Tozzoli R., Bizzaro N. Can supplementation with vitamin D reduce the risk or modify the course of autoimmune diseases? A systematic review of the literature. Autoimmun Rev 2012, 12:127-136.
60. Lucas R.M., Ponsonby A.L., Dear K., Valery P.C., Pender M.P., Taylor B.V., et al. Sun exposure and vitamin D are independent risk factors for CNS demyelination. Neurology 2011, 76:540-548.
61. Gilden D.H. Infectious causes of multiple sclerosis. Lancet Neurol 2005, 4:195-202.
62. Kakalacheva K., Lunemann J.D. Environmental triggers of multiple sclerosis. FEBS Lett 2011, 585(23):3724-3729.
63. Frohman E.M., Racke M.K., Raine C.S. Multiple sclerosis-the plaque and its pathogenesis. N Engl J Med 2006, 354:942-955.
64. Giovannoni G., Ebers G. Multiple sclerosis: the environment and causation. Curr Opin Neurol 2007, 20:261-268.
65. VanAmerongen B.M., Dijkstra C.D., Lips P., Polman C.H. Multiple sclerosis and vitamin D: an update. Eur J Clin Nutr 2004, 58:1095-1109.
66. Handel A.E., Giovannoni G., Ebers G.C., Ramagopalan S.V. Environmental factors and their timing in adult-onset multiple sclerosis. Nat Rev Neurol 2010, 6:156-166.
67. Handel A.E., Handunnetthi L., Giovannoni G., Ebers G.C., Ramagopalan S.V. Genetic and environmental factors and the distribution of multiple sclerosis in Europe. Eur J Neurol 2010, 17:1210-1214.
68. Mowry E.M., Krupp L.B., Milazzo M., Chabas D., Strober J.B., Belman A.L., et al. Vitamin D status is associated with relapse rate in pediatric-onset multiple sclerosis. Ann Neurol 2010, 67:618-624.
69. Simpson S., Taylor B., Blizzard L., Ponsonby A.L., Pittas F., Tremlett H., et al. Higher 25-hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis. Ann Neurol 2010, 68:193-203.
70. Smolders J., Menheere P., Kessels A., Damoiseaux J., Hupperts R. Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis. Mult Scler 2008, 14:1220-1224.
71. Grau-Lopez L., Granada M.L., Raich D., Naranjo M., Borras F.E., Martinez-Caceres E.M., et al. Regulatory role of vitamin D in T-cell reactivity against myelin peptides in relapsing-remitting multiple sclerosis patients. BMC Neurol 2012, 12:103.
72. Burton J.M., Kimball S., Vieth R., Bar-Or A., Dosch H.M., Cheung R., et al. A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology 2010, 74:1852-1859.
73. Decard B.F., von Ahsen N., Grunwald T., Streit F., Stroet A., Niggemeier P., et al. Low vitamin D and elevated immunoreactivity against Epstein-Barr virus before first clinical manifestation of multiple sclerosis. J Neurol Neurosurg Psychiatry 2012, 83(12):1170-1173.
74. Ascherio A., Munger K.L., Lennette E.T., Spiegelman D., Hernan M.A., Olek M.J., et al. Epstein-Barr virus antibodies and risk of multiple sclerosis: a prospective study. JAMA 2001, 286:3083-3088.
75. Levin L.I., Munger K.L., Rubertone M.V., Peck C.A., Lennette E.T., Spiegelman D., et al. Temporal relationship between elevation of epstein-barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis. JAMA 2005, 293:2496-2500.
76. Pender M.P. CD8+ T-cell deficiency, Epstein-Barr virus infection, vitamin D deficiency, and steps to autoimmunity: a unifying hypothesis. Autoimmun Dis 2012, 2012:189096.
77. Blank M., Gershwin M.E. Autoimmunity: from the mosaic to the kaleidoscope. J Autoimmun 2008, 30:1-4.
78. Anaya J.M., Corena R., Castiblanco J., Rojas-Villarraga A., Shoenfeld Y. The kaleidoscope of autoimmunity: multiple autoimmune syndromes and familial autoimmunity. Exp Rev Clin Immunol 2007, 3:623-635.
79. Zonana M.F., Reyes E., Weisman A.K. Coexistence of four autoimmune diseases in one patient: the kaleidoscope of autoimmunity. Clin Rheumatol 2002, 8:322-325.
80. Kaplan M.M., Gershwin M.E. Primary biliary cirrhosis. N Engl J Med 2005, 353:1261-1273.
81. Lleo A., Invernizzi P., Mackay I.R., Prince H., Zhong R.Q., Gershwin M.E. Etiopathogenesis of primary biliary cirrhosis. World J Gastroenterol 2008, 14:3328-3337.
82. Neuberger J. Primary biliary cirrhosis. Lancet 1997, 350:875-879.
83. Bogdanos D.P., Invernizzi P., Mackay I.R., Vergani D. Autoimmune liver serology: current diagnostic and clinical challenges. World J Gastroenterol 2008, 14:3374-3387.
84. Bogdanos D.P., Komorowski L. Disease-specific autoantibodies in primary biliary cirrhosis. Clin Chim Acta 2011, 412:502-512.
85. Dahnrich C., Pares A., Caballeria L., Rosemann A., Schlumberger W., Probst C., et al. New ELISA for detecting primary biliary cirrhosis-specific antimitochondrial antibodies. Clin Chem 2009, 55:978-985.
86. Liu H., Norman G.L., Shums Z., Worman H.J., Krawitt E.L., Bizzaro N., et al. PBC screen: an IgG/IgA dual isotype ELISA detecting multiple mitochondrial and nuclear autoantibodies specific for primary biliary cirrhosis. J Autoimmun 2010, 35:436-442.
87. Rigopoulou E.I., Davies E.T., Bogdanos D.P., Liaskos C., Mytilinaiou M., Koukoulis G.K., et al. Antimitochondrial antibodies of immunoglobulin G3 subclass are associated with a more severe disease course in primary biliary cirrhosis. Liver Int 2007, 27:1226-1231.
88. Vergani D., Bogdanos D.P. Positive markers in AMA-negative PBC. Am J Gastroenterol 2003, 98:241-243.
89. Invernizzi P., Lleo A., Podda M. Interpreting serological tests in diagnosing autoimmune liver diseases. Semin Liver Dis 2007, 27:161-172.
90. Metcalf J.V., Mitchison H.C., Palmer J.M., Jones D.E., Bassendine M.F., James O.F. Natural history of early primary biliary cirrhosis. Lancet 1996, 348:1399-1402.
91. Van de Water J., Fregeau D., Davis P., Ansari A., Danner D., Leung P., et al. Autoantibodies of primary biliary cirrhosis recognize dihydrolipoamide acetyltransferase and inhibit enzyme function. J Immunol 1988, 141:2321-2324.
92. Bogdanos D.P., Liaskos C., Pares A., Norman G., Rigopoulou E.I., Caballeria L., et al. Anti-gp210 antibody mirrors disease severity in primary biliary cirrhosis. Hepatology 2007, 45:1583. [author reply 1583-4].
93. Invernizzi P., Podda M., Battezzati P.M., Crosignani A., Zuin M., Hitchman E., et al. Autoantibodies against nuclear pore complexes are associated with more active and severe liver disease in primary biliary cirrhosis. J Hepatol 2001, 34:366-372.
94. Rigopoulou E.I., Davies E.T., Pares A., Zachou K., Liaskos C., Bogdanos D.P., et al. Prevalence and clinical significance of isotype specific antinuclear antibodies in primary biliary cirrhosis. Gut 2005, 54:528-532.
95. Courvalin J.C., Worman H.J. Nuclear envelope protein autoantibodies in primary biliary cirrhosis. Semin Liver Dis 1997, 17:79-90.
96. Bogdanos D.P., Mieli-Vergani G., Vergani D. Autoantibodies and their antigens in autoimmune hepatitis. Semin Liver Dis 2009, 29:241-253.
97. Invernizzi P., Selmi C., Ranftler C., Podda M., Wesierska-Gadek J. Antinuclear antibodies in primary biliary cirrhosis. Semin Liver Dis 2005, 25:298-310.
98. Bogdanos D.P., Pares A., Rodes J., Vergani D. Primary biliary cirrhosis specific antinuclear antibodies in patients from Spain. Am J Gastroenterol 2004, 99:763-764. [author reply 765].
99. Hirschfield G.M., Liu X., Han Y., Gorlov I.P., Lu Y., Xu C., et al. Variants at IRF5-TNPO3, 17q12-21 and MMEL1 are associated with primary biliary cirrhosis. Nat Genet 2010, 42:655-657.
100. Hirschfield G.M., Liu X., Xu C., Lu Y., Xie G., Gu X., et al. Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants. N Engl J Med 2009, 360:2544-2555.
101. Liu X., Invernizzi P., Lu Y., Kosoy R., Bianchi I., Podda M., et al. Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. Nat Genet 2010, 42:658-660.
102. Mells G.F., Floyd J.A., Morley K.I., Cordell H.J., Franklin C.S., Shin S.Y., et al. Genome-wide association study identifies 12 new susceptibility loci for primary biliary cirrhosis. Nat Genet 2011, 43:329-332.
103. Tanaka A., Ohira H., Kikuchi K., Nezu S., Shibuya A., Bianchi I., et al. Genetic association of Fc receptor-like 3 polymorphisms with susceptibility to primary biliary cirrhosis: ethnic comparative study in Japanese and Italian patients. Tissue Antigens 2011, 77:239-243.
104. Smyk D., Rigopoulou E.I., Baum H., Burroughs A.K., Vergani D., Bogdanos D.P. Autoimmunity and environment: am I at risk?. Clin Rev Allerg Immunol 2012, 42(2):199-212.
105. Smyk D.S., Mytilinaiou M.G., Milkiewicz P., Rigopoulou E.I., Invernizzi P., Bogdanos D.P. Towards systemic sclerosis and away from primary biliary cirrhosis: the case of PTPN22. Autoimmunity Highlights 2011, 3:1-9.
106. Corpechot C., Chretien Y., Chazouilleres O., Poupon R. Demographic, lifestyle, medical and familial factors associated with primary biliary cirrhosis. J Hepatol 2010, 53:162-169.
107. Gershwin M.E., Selmi C., Worman H.J., Gold E.B., Watnik M., Utts J., et al. Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients. Hepatology 2005, 42:1194-1202.
108. Prince M.I., Ducker S.J., James O.F. Case-control studies of risk factors for primary biliary cirrhosis in two United Kingdom populations. Gut 2010, 59:508-512.
109. Invernizzi P., Selmi C., Gershwin M.E. Update on primary biliary cirrhosis. Dig Liver Dis 2010, 42:401-408.
110. Selmi C., Invernizzi P., Zuin M., Podda M., Seldin M.F., Gershwin M.E. Genes and (auto)immunity in primary biliary cirrhosis. Genes Immun 2005, 6:543-556.
111. Smyk D., Cholongitas E., Kriese S., Rigopoulou E.I., Bogdanos D.P. Primary biliary cirrhosis: family stories. Autoimmune Dis 2011, 2011:189585.
112. Corpechot C., Gaouar F., Chretien Y., Johanet C., Chazouilleres O., Poupon R. Smoking as an independent risk factor of liver fibrosis in primary biliary cirrhosis. J Hepatol 2012, 56:218-224.
113. Invernizzi P. Human leukocyte antigen in primary biliary cirrhosis: an old story now reviving. Hepatology 2011, 54(2):714-723.
114. Hemminki K., Li X., Sundquist K., Sundquist J. Shared familial aggregation of susceptibility to autoimmune diseases. Arthritis Rheum 2009, 60:2845-2847.
115. Tanaka A., Invernizzi P., Ohira H., Kikuchi K., Nezu S., Kosoy R., et al. Replicated association of 17q12-21 with susceptibility of primary biliary cirrhosis in a Japanese cohort. Tissue Antigens 2011, 78:65-68.
116. Poupon R., Ping C., Chretien Y., Corpechot C., Chazouilleres O., Simon T., et al. Genetic factors of susceptibility and of severity in primary biliary cirrhosis. J Hepatol 2008, 49:1038-1045.
117. Invernizzi P., Miozzo M., Battezzati P.M., Bianchi I., Grati F.R., Simoni G., et al. Frequency of monosomy X in women with primary biliary cirrhosis. Lancet 2004, 363:533-535.
118. Invernizzi P., Pasini S., Selmi C., Gershwin M.E., Podda M. Female predominance and X chromosome defects in autoimmune diseases. J Autoimmun 2009, 33:12-16.
119. Miozzo M., Selmi C., Gentilin B., Grati F.R., Sirchia S., Oertelt S., et al. Preferential X chromosome loss but random inactivation characterize primary biliary cirrhosis. Hepatology 2007, 46:456-462.
120. Poupon R. Primary biliary cirrhosis: a 2010 update. J Hepatol 2010, 52:745-758.
121. Corpechot C., Carrat F., Poupon R., Poupon R.E. Primary biliary cirrhosis: incidence and predictive factors of cirrhosis development in ursodiol-treated patients. Gastroenterology 2002, 122:652-658.
122. Corpechot C., Abenavoli L., Rabahi N., Chretien Y., Andreani T., Johanet C., et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology 2008, 48:871-877.
123. Corpechot C., Chazouilleres O., Poupon R. Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome. J Hepatol 2011, 55:1361-1367.
124. Corpechot C., Carrat F., Bahr A., Chretien Y., Poupon R.E., Poupon R. The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology 2005, 128:297-303.
125. Poupon R. Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action. Clin Res Hepatol Gastroenterol 2012, 36(Suppl. 1):S3-S12.
126. Serfaty L., Poupon R. Therapeutic approaches for hepatobiliary disorders with ursodeoxycholic acid and bile-acid derivatives. Clin Res Hepatol Gastroenterol 2012, 36(Suppl. 1):S1.
127. Pares A., Guanabens N., Rodes J. Gene polymorphisms as predictors of decreased bone mineral density and osteoporosis in primary biliary cirrhosis. Eur J Gastroenterol Hepatol 2005, 17:311-315.
128. Corpechot C., Poupon R. Geotherapeutics of primary biliary cirrhosis: bright and sunny around the Mediterranean but still cloudy and foggy in the United Kingdom. Hepatology 2007, 46:963-965.
129. D'Aldebert E., Biyeyeme Bi Mve M.J., Mergey M., Wendum D., Firrincieli D., Coilly A., et al. Bile salts control the antimicrobial peptide cathelicidin through nuclear receptors in the human biliary epithelium. Gastroenterology 2009, 136:1435-1443.
130. Almerighi C., Bogdanos D., Cholongitas V., Carey I., Meda E., Hussain M., et al. 626 In vitro immunosuppressive effect of vitamin D3 in primary biliary cirrhosis. J Hepatol 2006, 44:S232-S233.
131. Arteh J., Narra S., Nair S. Prevalence of vitamin D deficiency in chronic liver disease. Dig Dis Sci 2010, 55:2624-2628.
132. Bando H., Hashimoto N., Hirota Y., Sakaguchi K., Hisa I., Inoue Y., et al. Severe hypophosphatemic osteomalacia with Fanconi syndrome, renal tubular acidosis, vitamin D deficiency and primary biliary cirrhosis. Intern Med 2009, 48:353-358.
133. Fan L., Tu X., Zhu Y., Zhou L., Pfeiffer T., Feltens R., et al. Genetic association of vitamin D receptor polymorphisms with autoimmune hepatitis and primary biliary cirrhosis in the Chinese. J Gastroenterol Hepatol 2005, 20:249-255.
134. Guardiola J., Xiol X., Nolla J.M. Influence of vitamin D receptor gene polymorphism on bone mineral density in primary biliary cirrhosis. Gastroenterology 2000, 119:599-600.
135. Halmos B., Szalay F., Cserniczky T., Nemesanszky E., Lakatos P., Barlage S., et al. Association of primary biliary cirrhosis with vitamin D receptor BsmI genotype polymorphism in a Hungarian population. Dig Dis Sci 2000, 45:1091-1095.
136. Kempinska-Podhorecka A., Wunsch E., Jarowicz T., Raszeja-Wyszomirska J., Loniewska B., Kaczmarczyk M., et al. Vitamin d receptor polymorphisms predispose to primary biliary cirrhosis and severity of the disease in polish population. Gastroenterol Res Pract 2012, 2012:408723.
137. Lakatos L.P., Bajnok E., Hegedus D., Toth T., Lakatos P., Szalay F. Vitamin D receptor, oestrogen receptor-alpha gene and interleukin-1 receptor antagonist gene polymorphisms in Hungarian patients with primary biliary cirrhosis. Eur J Gastroenterol Hepatol 2002, 14:733-740.
138. Malham M., Jorgensen S.P., Ott P., Agnholt J., Vilstrup H., Borre M., et al. Vitamin D deficiency in cirrhosis relates to liver dysfunction rather than aetiology. World J Gastroenterol 2011, 17:922-925.
139. Mascitelli L., Pezzetta F., Goldstein M.R. Primary biliary cirrhosis, falls and the vitamin D endocrine system. QJM 2010, 103:437-438. [author reply 438-9].
140. Resnick R.H., Chopra S. Vitamin D receptor gene analysis in primary biliary cirrhosis. Gastroenterology 2000, 119:1805.
141. Springer J.E., Cole D.E., Rubin L.A., Cauch-Dudek K., Harewood L., Evrovski J., et al. Vitamin D-receptor genotypes as independent genetic predictors of decreased bone mineral density in primary biliary cirrhosis. Gastroenterology 2000, 118:145-151.
142. Tanaka A., Nezu S., Uegaki S., Kikuchi K., Shibuya A., Miyakawa H., et al. Vitamin D receptor polymorphisms are associated with increased susceptibility to primary biliary cirrhosis in Japanese and Italian populations. J Hepatol 2009, 50:1202-1209.
143. Vogel A., Strassburg C.P., Manns M.P. Genetic association of vitamin D receptor polymorphisms with primary biliary cirrhosis and autoimmune hepatitis. Hepatology 2002, 35:126-131.
144. Czaja A.J. Autoimmune hepatitis-approach to diagnosis. Med Gen Med 2006, 8:55.
145. Maggs J., Cullen S. Management of autoimmune liver disease. Minerva Gastroenterol Dietol 2009, 55:173-206.
146. Longhi M.S., Ma Y., Bogdanos D.P., Cheeseman P., Mieli-Vergani G., Vergani D. Impairment of CD4(+)CD25(+) regulatory T-cells in autoimmune liver disease. J Hepatol 2004, 41:31-37.
147. Longhi M.S., Hussain M.J., Mitry R.R., Arora S.K., Mieli-Vergani G., Vergani D., et al. Functional study of CD4+CD25+regulatory T cells in health and autoimmune hepatitis. J Immunol 2006, 176:4484-4491.
148. Bettelli E., Carrier Y., Gao W., Korn T., Strom T.B., Oukka M., et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006, 441:235-238.
149. Jorgensen R.A., Lindor K.D., Sartin J.S., LaRusso N.F., Wiesner R.H. Serum lipid and fat-soluble vitamin levels in primary sclerosing cholangitis. J Clin Gastroenterol 1995, 20:215-219.